Dr. Timothy L Barr, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2000 Eoff St, Emp Office, Wheeling, WV 26003 Phone: 304-234-8425 |
Jarryd Austin Reed, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Eoff St, Wheeling, WV 26003 Phone: 304-234-8177 |
Tyler Sieron, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Eoff St, Wheeling, WV 26003 Phone: 304-234-0123 |
Dr. Matthew P Fox, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Park, Wheeling, WV 26003 Phone: 304-243-3124 Fax: 304-243-6343 |
Dr. Michael David Mcdonald, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2000 Eoff St, Wheeling, WV 26003 Phone: 304-234-8177 |
Dr. Jennifer Cantrell Adkins, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2000 Eoff St, Wheeling, WV 26003 Phone: 304-234-8177 |
Dr. Patrick Johnmichael Connolly, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Eoff St, Wheeling, WV 26003 Phone: 304-234-0123 |
News Archive
When a person contracts Lyme disease, quick diagnosis and treatment are essential to avoiding long term complications. But the diagnostic process may be delayed if a physician does not recognize a skin rash caused by Lyme disease because it does not have the bull's-eye appearance that is best known to physicians and the public.
Although skin disease can affect anyone, it may not affect everyone in the same way -; and this is especially true for patients with skin of color.
A small trial suggests that treatment with intravenous and oral antiviral medications may reduce the nerve pain that occurs following shingles, according to a study posted online today that will appear in the July 2006 print issue of Archives of Neurology.
The International Vaccine Institute (IVI) hosted a virtual State Forum today to advocate for multilateral cooperation through vaccine diplomacy.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.
› Verified 6 days ago